File Download
  Links for fulltext
     (May Require Subscription)

Article: Liquid Biopsy Serial Monitoring of Treatment Responses and Relapse in Advanced Esophageal Squamous Cell Carcinoma

TitleLiquid Biopsy Serial Monitoring of Treatment Responses and Relapse in Advanced Esophageal Squamous Cell Carcinoma
Authors
Keywordscirculating tumor cells
cell-free DNA
CTC enumeration
longitudinal real-time monitoring
non-invasive biomarker
Issue Date2020
PublisherMDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/cancers/
Citation
Cancers, 2020, v. 12 n. 6, p. article no. 1352 How to Cite?
Abstract(1) Background: Early predictive markers to track treatment responses are needed for advanced esophageal squamous cell carcinoma (ESCC) patients. We examined the prognostication and risk stratification role of liquid biopsy serial monitoring for this deadly cancer. (2) Methods: Circulating tumor cells (CTCs) and plasma cell-free DNA (cfDNA) were isolated from 60 ESCC patients treated by chemotherapy (CT) at five serial timepoints: baseline (CTC1/cfDNA1), CT pre-cycle III (CTC2/cfDNA2), CT post-cycle IV, end of CT and relapse. (3) Results: In 45/57 ESCC patients with evaluable CTC counts at CT pre-cycle III, positive CTC2 (≥3 CTCs) is independently associated with response at interim reassessment and progression-free survival (PFS) in multivariate analysis. In 42/57 ESCC patients with changes of CTC1/CTC2 and cfDNA1/cfDNA2, patients categorized into four risk groups based on the number of favorable and unfavorable changes of CTC1/CTC2 and cfDNA1/cfDNA2, were independently associated with overall survival (OS) by multivariate analysis. (4) Conclusions: CTC counts at pre-cycle III are independently associated with response at interim reassessment and PFS. Combined changes of CTC counts and cfDNA levels from baseline to pre-cycle III are independently associated with OS. Longitudinal liquid biopsy serial monitoring provides complementary information for prediction and prognosis for CT responses in advanced ESCC.
Persistent Identifierhttp://hdl.handle.net/10722/285274
ISSN
2023 Impact Factor: 4.5
2023 SCImago Journal Rankings: 1.391
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKo, JMY-
dc.contributor.authorNg, HY-
dc.contributor.authorLam, KO-
dc.contributor.authorChiu, KWH-
dc.contributor.authorKwong, DLW-
dc.contributor.authorLo, AWI-
dc.contributor.authorWong, JC-
dc.contributor.authorLin, RCW-
dc.contributor.authorFong, HCH-
dc.contributor.authorLi, JYK-
dc.contributor.authorDai, W-
dc.contributor.authorLaw, S-
dc.contributor.authorLung, ML-
dc.date.accessioned2020-08-18T03:51:55Z-
dc.date.available2020-08-18T03:51:55Z-
dc.date.issued2020-
dc.identifier.citationCancers, 2020, v. 12 n. 6, p. article no. 1352-
dc.identifier.issn2072-6694-
dc.identifier.urihttp://hdl.handle.net/10722/285274-
dc.description.abstract(1) Background: Early predictive markers to track treatment responses are needed for advanced esophageal squamous cell carcinoma (ESCC) patients. We examined the prognostication and risk stratification role of liquid biopsy serial monitoring for this deadly cancer. (2) Methods: Circulating tumor cells (CTCs) and plasma cell-free DNA (cfDNA) were isolated from 60 ESCC patients treated by chemotherapy (CT) at five serial timepoints: baseline (CTC1/cfDNA1), CT pre-cycle III (CTC2/cfDNA2), CT post-cycle IV, end of CT and relapse. (3) Results: In 45/57 ESCC patients with evaluable CTC counts at CT pre-cycle III, positive CTC2 (≥3 CTCs) is independently associated with response at interim reassessment and progression-free survival (PFS) in multivariate analysis. In 42/57 ESCC patients with changes of CTC1/CTC2 and cfDNA1/cfDNA2, patients categorized into four risk groups based on the number of favorable and unfavorable changes of CTC1/CTC2 and cfDNA1/cfDNA2, were independently associated with overall survival (OS) by multivariate analysis. (4) Conclusions: CTC counts at pre-cycle III are independently associated with response at interim reassessment and PFS. Combined changes of CTC counts and cfDNA levels from baseline to pre-cycle III are independently associated with OS. Longitudinal liquid biopsy serial monitoring provides complementary information for prediction and prognosis for CT responses in advanced ESCC.-
dc.languageeng-
dc.publisherMDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/cancers/-
dc.relation.ispartofCancers-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectcirculating tumor cells-
dc.subjectcell-free DNA-
dc.subjectCTC enumeration-
dc.subjectlongitudinal real-time monitoring-
dc.subjectnon-invasive biomarker-
dc.titleLiquid Biopsy Serial Monitoring of Treatment Responses and Relapse in Advanced Esophageal Squamous Cell Carcinoma-
dc.typeArticle-
dc.identifier.emailKo, JMY: joko@hku.hk-
dc.identifier.emailNg, HY: hyng0812@hku.hk-
dc.identifier.emailLam, KO: lamkaon@hku.hk-
dc.identifier.emailChiu, KWH: kwhchiu@hku.hk-
dc.identifier.emailKwong, DLW: dlwkwong@hku.hk-
dc.identifier.emailWong, JC: ever5js@hku.hk-
dc.identifier.emailLin, RCW: rogerlin@HKUCC-COM.hku.hk-
dc.identifier.emailFong, HCH: fchhenry@hku.hk-
dc.identifier.emailLi, JYK: ykjli@HKUCC-COM.hku.hk-
dc.identifier.emailDai, W: weidai2@hku.hk-
dc.identifier.emailLaw, S: slaw@hku.hk-
dc.identifier.emailLung, ML: mlilung@hku.hk-
dc.identifier.authorityKo, JMY=rp02011-
dc.identifier.authorityLam, KO=rp01501-
dc.identifier.authorityChiu, KWH=rp02074-
dc.identifier.authorityKwong, DLW=rp00414-
dc.identifier.authorityDai, W=rp02146-
dc.identifier.authorityLaw, S=rp00437-
dc.identifier.authorityLung, ML=rp00300-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3390/cancers12061352-
dc.identifier.scopuseid_2-s2.0-85085549584-
dc.identifier.hkuros312654-
dc.identifier.volume12-
dc.identifier.issue6-
dc.identifier.spagearticle no. 1352-
dc.identifier.epagearticle no. 1352-
dc.identifier.isiWOS:000549339600001-
dc.publisher.placeSwitzerland-
dc.identifier.issnl2072-6694-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats